Letrozole Accord

Letrozole, the active ingredient in Letrozole Accord, is an aromatase inhibitor presented as a tablet (strength not disclosed) for oral use. It works by lowering estrogen production and is indicated for the treatment of estrogen receptor‑positive breast cancer in postmenopausal women, both in early‑stage adjuvant settings and in metastatic disease.

GNH USA supplies Letrozole Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, providing reliable access to quality‑assured medicines. All batches meet EU pharmacopeial standards.

Letrozole is used in the hormonal management of estrogen‑driven breast cancer.

Estrogen receptor‑positive breast cancer (postmenopausal): reduces tumor growth by decreasing circulating estrogen levels. Adjuvant therapy for early‑stage ER+ breast cancer (postmenopausal): helps prevent disease recurrence after surgery. Metastatic ER+ breast cancer (postmenopausal): provides disease control and prolongs progression‑free survival.

Adverse reactions may occur with Letrozole therapy and are categorized by frequency.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe liver injury - Osteoporotic fractures - Deep vein thrombosis or pulmonary embolism - Myocardial infarction - Anaphylactic or severe allergic reaction - Hypercholesterolemia

Before initiating Letrozole, several safety considerations should be reviewed.

Pregnancy contraindication: drug is teratogenic (Category X) and must not be used in pregnant women. Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. Liver function assessment: obtain baseline hepatic enzymes and monitor periodically. Cardiovascular risk evaluation: review history of thromboembolic events or myocardial disease. Use only in postmenopausal patients: avoid in premenopausal women unless ovarian suppression is confirmed. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Letrozole may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness. - Estrogen‑containing hormone therapy: antagonizes therapeutic intent. - Tamoxifen: combined use can diminish anti‑estrogenic benefit. - Warfarin: may potentiate anticoagulant effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): possible modest effect on metabolism. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for gastrointestinal irritation. - Statins: observe for altered lipid profile. - Anticonvulsants (e.g., carbamazepine): may affect drug levels. - Antifungal agents (e.g., fluconazole): may require dose adjustment.